07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Biocoll GmbH, Genfit, University of Freiburg deal

The partners began the OLNORME II program to develop candidates targeting an undisclosed nuclear orphan receptor from plant metabolites to prevent and treat cardiovascular, metabolic and neurodegenerative diseases, including atherosclerosis, Type II diabetes, obesity and...
07:00 , May 5, 1997 |  BC Week In Review  |  Company News

Biocoll board of directors update

Biocoll Medical Corp. (VSE:BLM), Vancouver, B.C.   Business: Musculoskeletal   Appointed: Ian Lennox, president and CEO of Drug Royalty Corp.; Clifford Nordal, president and CEO of Queen Elizabeth Hospital and assistant professor, faculty of medicine,...
08:00 , Jan 27, 1997 |  BC Week In Review  |  Company News

Biocoll, Osteopharm Ltd. deal

BLM completed its acquisition of Osteopharm, a developer of osteoporosis compounds, by issuing 9.2 million shares of BLM to Osteopharm's existing shareholders. Concurrently, BLM raised C$10 million in a private placement (details, B15). Osteopharm has...